Implications of genetic testing and informed consent before and after genetic testing in individuals with cancer  

作　　者：Priyanka Kumar David J Benjamin Sourat Darabi Goetz Kloecker Arash Rezazadeh Kalebasty 

机构地区：[1]Department of Hematology and Medical Oncology,Harbor-UCLA Medical Center,Torrance,CA 90502,United States [2]Department of Medical Oncology,Hoag Family Cancer Institute,Newport Beach,CA 92663,United States [3]Department of Precision Medicine,Hoag Family Cancer Institute,Newport Beach,CA 92663,United States [4]Department of Hematology and Medical Oncology,University of Louisville,Louisville,KY 40202,United States [5]Department of Hematology and Medical Oncology,University of California-Irvine,Orange,CA 92868,United States

出　　处：《World Journal of Clinical Oncology》2024年第8期975-981,共7页世界临床肿瘤学杂志（英文版）

摘　　要：Recent advancements in next generation sequencing have allowed for genetic information become more readily available in the clinical setting for those affected by cancer and by treating clinicians.Given the lack of access to geneticists,medical oncologists and other treating physicians have begun ordering and interpreting genetic tests for individuals with cancer through the process of"mainstreaming".While this process has allowed for quicker access to genetic tests,the process of"mainstreaming"has also brought several challenges including the dissemination of variants of unknown significance results,ordering of appropriate tests,and accurate interpretation of genetic results with appropriate followup testing and interventions.In this editorial,we seek to explore the process of informed consent of individuals before obtaining genetic testing and offer potential solutions to optimize the informed consent process including categorization of results as well as a layered consent model.

关 键 词：Genetic testing Informed consent Genetic counseling Next generation sequencing MAINSTREAMING Layered consent 

分 类 号：R73[医药卫生—肿瘤]